Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Myasthenia gravis (MG) is an acquired autoimmune neuromuscular junction disorder characterized by fluctuating skeletal muscle weakness. No heritable causative gene variants or Mendelian inheritance patterns are documented in this packet. Recognized subtypes in this packet include AChR antibody-positive, MuSK antibody-positive, LRP4 antibody-positive, and seronegative forms.
Phenotypic data and characteristic clinical findings are not established in this packet's structured fields.
MG is an acquired autoimmune condition with no causative genes or inheritance patterns documented in this packet, consistent with immune-mediated pathophysiology.
Diagnostic criteria are not established in this packet's structured fields.
Eight FDA-approved therapies with active market status are documented in this packet for MG: eculizumab (SOLIRIS, BLA 2017), ravulizumab (ULTOMIRIS; packet records a 2018 date reflecting initial BLA approval for a different indication — MG-specific approval June 2023), efgartigimod alfa (VYVGART, BLA December 2021), efgartigimod alfa/hyaluronidase-zzxf (VYVGART HYTRULO, BLA June 2023), rozanolixizumab (RYSTIGGO, BLA June 2023), zilucoplan (ZILBRYSQ, NDA October 2023), nipocalimab (IMAAVY, BLA April 2025), and inebilizumab (UPLIZNA; packet records a June 2020 date reflecting initial approval for a different indication).
165 trials found
Prognostic information is not established in this packet's structured fields.
Two recruiting trials are documented in this packet for MG. NCT06718803 is a Phase 1 study of RVT-2201 in AChR antibody-positive generalized MG, sponsored by Immunovant Sciences, with planned completion September 2027. NCT07150284 is a Phase 1 study of miplastide, sponsored by INSERM, beginning June 2026 with planned completion June 2028.
Data assembled from 7 of 12 sources · Last updated Sep 19, 2026, 6:00 AM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning myasthenia gravis
Updated Sep 7, 2026
A population-based study examines medication use trajectories during pregnancies in women with myasthenia gravis. This research provides insights into treatment patterns and potential implications for maternal and fetal health.
A nationwide cohort study highlights the prevalence of non-motor symptoms and healthcare utilization prior to the diagnosis of myasthenia gravis. This research underscores the need for increased awareness and early detection strategies for this rare disease.
A prespecified analysis from the Phase 3 trial of inebilizumab for myasthenia gravis highlights its effectiveness in managing exacerbations and rescue therapy. This study contributes valuable insights into treatment strategies for this rare neuromuscular disorder.